Drug intelligence / Profile preview

VPS72-H2A.Z interaction blocking peptide

Development stage
Preclinical
Lead developer
Henry Ford Health
Modality
Peptides
01

Overview

The VPS72-H2A.Z interaction blocking peptide is an experimental cell-permeable therapeutic agent designed to disrupt the binding between the histone chaperone VPS72 and the histone variant H2A.Z. VPS72 is a shared subunit of the SRCAP and TIP60 remodeling complexes and is responsible for the ATP-dependent deposition of H2A.Z-H2B dimers into regulatory chromatin. In lung adenocarcinoma (LUAD), this axis is frequently upregulated and supports oncogenic transcriptional programs, including MYC- and E2F-driven cell-cycle progression, metabolic adaptation, and immune evasion. By blocking the VPS72-H2A.Z interface, the peptide prevents the incorporation of H2A.Z into DNA, thereby inducing apoptosis and inhibiting the proliferation, migration, and invasion of cancer cells. This epigenetic modulator represents a novel strategy to overcome therapeutic resistance and plasticity in aggressive non-small cell lung cancer.

Other names
VPS72-H2A.Z inhibitor peptideVPS-72-H2A.Z inhibitor peptideVPS 72-H2A.Z inhibitor peptide
02

Targets

H2A.Z (Histone H2A.Z variant 1)

Beyond the preview

Go deeper on VPS72-H2A.Z interaction blocking peptide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on VPS72-H2A.Z interaction blocking peptide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call